Quadrature Capital Ltd Makes New $10.77 Million Investment in Edwards Lifesciences Co. (NYSE:EW)

Quadrature Capital Ltd acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 163,220 shares of the medical research company’s stock, valued at approximately $10,771,000.

Other hedge funds also recently added to or reduced their stakes in the company. BDF Gestion acquired a new position in Edwards Lifesciences during the 2nd quarter worth $5,148,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after buying an additional 40,348 shares during the last quarter. Raymond James & Associates lifted its position in shares of Edwards Lifesciences by 2.8% in the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after buying an additional 50,124 shares during the last quarter. AIA Group Ltd lifted its position in shares of Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after buying an additional 358,556 shares during the last quarter. Finally, RiverPark Advisors LLC lifted its position in shares of Edwards Lifesciences by 58.1% in the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock worth $1,362,000 after buying an additional 7,583 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW opened at $74.21 on Thursday. The firm’s 50 day moving average is $68.42 and its 200-day moving average is $74.77. The stock has a market capitalization of $43.77 billion, a P/E ratio of 10.71, a P/E/G ratio of 3.95 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.59 EPS. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent research reports. Canaccord Genuity Group reduced their price target on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $75.00 to $80.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 27th. Truist Financial reduced their price target on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $77.25.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock valued at $2,657,000 in the last quarter. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.